ArticleArchives of dermatological research2025
Claudin-1 expression in acne and its correlation with disease severity: clinical and in silico validation.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pilosebaceous unit is the site of a common chronic inflammatory skin disorder called acne. Tight junctions (TJ) are present in sebocytes and are primarily composed of claudin-1. When claudin-1 is knocked down, the TJ barrier leaks, and holocrine secretion is compromised. This leads to the accumulation of partially degenerated sebocytes in the pilosebaceous ducts and the creation of microcomedos, which can cause acne lesions. The study's aim was to measure the claudin-1 gene and protein expression in acne patients' blood samples and establish a correlation with the severity of the condition and their levels. 48 acne patients were involved and 48 matched control for age and sex. First samples were obtained from both groups and RNA was extracted from the whole blood sample followed by qPCR to measure the relative expression of the claudin-1 gene. Enzyme-linked immunosorbent assay (ELISA) was used to measure claudin-1 protein level. There were statistically significant lower relative expression of claudin-1 gene (p = 0.001) and its protein level (p = 0.001) in acne patients compared to controls (0.34 ± 0.32 vs 1.0 ± 0.0, 0.64 ± 0.62 vs 3.85 ± 2.14, respectively). There was a statistically significant inverse correlation between claudin-1 protein expression and acne severity (R = -0.374, p = 0.009). Computational and bioinformatics tools were used for enrichment analysis to better understand claudin-1 role in the context of the disease and provide possible therapeutic approaches. Claudin-1 dysregulation in acne patients, suggest that it have an impact on the severity and course of acne through affecting the epidermal barrier and facilitating inflammation.
Indexed as
Identifiers
40156623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.